VIVUS Inc. (VVUS) Drops 5.7% on January 11

Equities Staff |

VIVUS Inc. (VVUS) was one of the Russell 2000's biggest losers for Monday January 11 as the stock slid 5.7% to $0.99, a loss of $-0.0599 per share. Starting at an opening price of $1.05 a share, the stock traded between $0.96 and $1.08 over the course of the trading day. Volume was 1.47 million shares over 3,218 trades, against an average daily volume of 2.89 million shares and a total float of 104.04 million.

The losses send VIVUS Inc. down to a market cap of $103.01 million. In the last year, VIVUS Inc. has traded between $3.40 and $0.94, and its 50-day SMA is currently $1.21 and 200-day SMA is $1.79.

Vivus is a biopharmaceutical company engaged in the development and commercialization of therapeutic products for large underserved markets. Its product line includes Qsymia for sleep apnea, STENDRA for erectile dysfunction.

VIVUS Inc. is based out of Mountain View, CA and has some 94 employees. Its CEO is Seth H.Z. Fischer.

For a complete fundamental analysis analysis of VIVUS Inc., check out’s Stock Valuation Analysis report for VVUS. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth

Propanc Health Group Corp

Propanc Health Group Corp is an early stage healthcare company. It is engaged in developing new cancer treatments for patients, suffering from pancreatic and colorectal cancer.

Private Markets


Cloudera offers enterprises a new data platform built on the Apache Hadoop open-source software package. Hadoop is a data-management platform that can consolidate data in a single repository for comprehensive…

XY Find It

Founded by serial entrepreneur Arie Trouw, XY Findables follows a single guiding principle: customers should never lose anything important again. With over 50,000 users around the world, more than 100,000…